A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder

NCT00246246 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Disorder

Interventions

DRUG: risperidone

Sponsor

Janssen-Ortho Inc., Canada